CD147 Sparks Atherosclerosis by Driving M1 Phenotype and Impairing Efferocytosis.
Jian-Jun LvHao WangCong ZhangTian-Jiao ZhangHao-Lin WeiZe-Kun LiuYi-Hui MaZhi YangQian HeLi-Juan WangLi-Li DuanZhi-Nan ChenHui-Jie BianPublished in: Circulation research (2024)
Myeloid CD147 plays a crucial role in the growth of plaques by promoting inflammation in a TRAF6-IKK-IRF5-dependent manner and inhibiting efferocytosis by suppressing GAS6 during proinflammatory conditions. Consequently, the use of anti-human CD147 antibodies presents a complementary therapeutic approach to the existing lipid-lowering strategies for treating atherosclerotic diseases.